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Introduction
Percutaneous coronary intervention and stenting is the most 
commonly used treatment for coronary artery disease. Plain-
old balloon angioplasty (POBA) was the first technique (1) 
which facilitated a minimally-invasive expansion of a 
stenosed coronary artery (2). The technique was limited 
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by acute complications including coronary dissection, 
which in some patients progressed to abrupt vessel closure 
requiring emergency bypass surgery; and acute elastic recoil, 
reducing the luminal gain following balloon dilatation. Post-
procedure, restenosis due to neointimal proliferation of 
vascular smooth muscle cells represented another limiting 
factor most common in patients with diabetes and complex 
coronary artery disease (3-5).
Bare-metal stents (BMS) virtually solved the problem of 
dissection; acute vessel closure and the need for emergency 
bypass surgery (2), but did not reduce the risk of restenosis. 
The implantation of stents also led to a new problem of 
acute, late and very late stent thrombosis (6). However, 
treatment with dual antiplatelet therapy (DAPT) reduced 
this risk (7). The introduction of drug-eluting stents (DES) 
and its generational enhancements (i.e., thinner struts) 
partially resolved the problem of restenosis through release 
of anti-mitotic agents but concerns surrounding prolonged 
DAPT still remained (8,9).
To overcome the limitations of POBA, BMS and DES, 
the drug-eluting balloons (DEB) was developed. Initially 
introduced as a treatment for in-stent restenosis (ISR) in 
BMS and DES-lesions (10) they have emerged as a potential 
treatment for de novo coronary lesions. This is because the 
DEB intervention has several advantages over DES such 
as homogenous transfer of drug across vessel wall, lack of 
foreign body implantation, reduced bleeding risk (1 month 
DAPT versus 6–12 months of therapy for DES) and access 
to complex lesions (4,11). However, one disadvantage is 
that in a small proportion of DEB-treated patients, bail-
out stenting is required, following recoil or dissections (12). 
Despite the promising characteristics of this intervention 
type, the indication for DEB use in de novo coronary lesions 
is still unclear.
Previous meta-analyses have failed to address the DEB-
only strategy for de novo coronary artery disease (13,14). 
Moreover, analyses have not yet explored a DEB-only 
approach in bifurcation lesions. As initial studies suggest 
that DEB-alone show success for treatment of high-
risk restenotic areas (15,16), we hypothesised that DEB 
will also provide superior results compared with other 
interventional treatments, for the treatment of small 
vessel disease and bifurcation lesions in de novo coronary 
disease. This study, which includes data from DEB and 
adjunctive BMS as well as DEB-only studies, therefore 
aims to provide the most up-to-date and comprehensive 
systematic review and meta-analysis for the treatment of 
de novo coronary artery disease. The safety and efficacy of 
DEB (with or without BMS) will be compared to other 
conventional management options (POBA, BMS and 
DES) in treating de novo lesions. 
Methods
This study was performed in accordance with the Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses 
(PRISMA) guidelines.
Literature search
MEDLINE, Embase, PubMed and ClinicalTrials.gov were 
searched for RCTs published from 1st January 2000 through 
to 1st May 2017 using the key terms: ‘drug eluting balloon’, 
‘drug coated balloon’, ‘paclitaxel eluting balloon’, ‘de novo 
coronary lesion’, ‘coronary stenosis’, ‘coronary disease’, 
‘small vessel disease’, ‘bifurcation’, ‘complex long lesion’, 
‘acute myocardial infarction’, ‘acute MI’ and ‘MI’. No 
filters were applied. Abstracts and conference proceedings 
of the American College of Cardiology and Transcatheter 
Cardiovascular Therapeutics Symposia were also screened. 
References included in literature reviews were searched 
manually to ensure all studies that complied with the 
inclusion criteria were identified. Two investigators (S Patel 
and T Svermova) independently reviewed the resulting 
articles. A qualitative risk of bias in seven domains (random 
sequence generation; allocation concealment; blinding of 
participants/personnel; outcome; incomplete outcome; 
selective reporting and other risk of bias) was conducted. 
Study selection
We included all studies that compared angioplasty using 
the DEB-only strategy as well as DEB with adjunctive BMS 
to: POBA, BMS and DES. For analysis, data pertaining 
to the longest available follow up periods were used. 
Exclusion criteria were patients treated for ISR and use of 
interventions other than DEB, POBA, BMS or DES (e.g., 
endothelial progenitor capturing stents). Non-randomised 
controlled trials and non-observational studies were also 
excluded. The primary endpoint collected was in-segment 
or in-stent late lumen loss (LLL). Secondary angiographic 
and clinical endpoints were: binary restenosis (in-stent or 
in-segment), target lesion revascularization (TLR), major 
adverse cardiac events (MACE), myocardial infarction (MI) 
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and cardiac death.
Statistical analysis
Statistical analysis was performed using standard software 
packages (Review Manager version 5.3, The Nordic 
Cochrane Centre, The Cochrane Collaboration, 2014, 
Copenhagen, Norway; Comprehensive Meta-analysis 
version 3 software, Biostat Inc., Englewood, NJ, USA) with 
two-tailed P values <0.05 considered significant. Analyses 
are presented as forest plots—the conventional method 
for showing results from individual studies and meta-
analysis. Risk ratios (RRs) with 95% confidence intervals 
(CIs) or mean differences (MDs) with standard deviations 
are presented as summary statistics. Subgroup analyses 
comparing DEB-only studies with DES were also performed. 
Heterogeneity between studies was compared by Q and I2 
statistics (respectively, P<0.1 indicates heterogeneity; <25%, 
25–50% and >50% indicate low, medium and high levels). 
Studies were combined using the random effect model. 
Publication bias was assessed using funnel plots and Egger’s 
test (P<0.05 indicates significant bias).
Results
A PRISMA diagram of the literature search and the 
subsequent selection is presented in Figure 1. In total, 
606 articles were retrieved. Following screening for 
replicates, 405 remained; and after screening abstracts for 
relevance, a further 371 studies were removed. Finally, full 
text of the remaining 34 studies were screened, of which 17 
randomised controlled trials (17-34) fulfilled the inclusion 
criteria and were qualitatively and quantitatively analysed. 
Characteristics of the patients and study designs
A summary of the included studies is provided in Table 1 
and this table also documents: (I) interventions compared; 
(II) DEB, DES and BMS type; (III) indication; (IV) 
primary endpoint; (V) percent bare metal stenting; and (VI) 
angiographic follow-up time. 
A total of 2,616 patients, ranging from 30 to 637 per study, 
were enrolled in the meta-analysis. There were 1,218 patients 
treated with DEB + BMS; whereas, 347 were treated with 
BMS; 1,028 with DES; and 32 with POBA. The mean age 
of patients recruited was 65 years; and all of the studies had 
a majority of male patients. Studies recruited from different 
patient populations. In the trial by Ali and colleagues (31), all 
patients were diabetic; whereas, in trials conducted by Besic 
et al. (23) and Poerner et al. (25) all patients were 
hypertensive. Data for each trial are detailed in Table 2.
Risk of bias analysis revealed high-risk bias in open-label 
studies (17,22,27) and incomplete outcome data (25,27,30) 
where greater than 15% of patients were lost to follow-up 
(Table 3). 
LLL
In subset analyses, DEB + BMS compared more favourably 
to POBA with a statistically significant difference observed 
for LLL [MD =−0.39; (−0.67 to −0.11); P=0.006]. DEB + 
BMS also had a significantly lower rate of LLL compared 
to the BMS group [MD =−0.27; (−0.45 to −0.10); P=0.002]. 
When compared to the DES group, the DEB + BMS group 
had an increased LLL and therefore was significantly less 
effective than DES [MD =0.12; (0.03 to 0.22); P=0.01] 
(Figure 2). 
Binary restenosis
In subset analyses, risk of binary restenosis in the DEB + 
BMS group was significantly lower compared to the POBA 
group [RR =0.20; (0.05 to 0.85); P=0.03]. This was also 
seen in the DEB + BMS and DES groups, where binary 
restenosis was significantly lower in the former mode of 
intervention [RR =1.89; (1.13 to 3.18); P=0.02]. There was 
no statistically significant difference in binary restenosis, 
however, between the DEB + BMS and BMS groups [RR 
=0.44; (0.18 to 1.06); P=0.07] (Figure 3).
TLR
Compared to the BMS group, the DEB + BMS group had 
a significantly lower need for TLR [RR =0.65; (0.44 to 
0.97); P=0.04]. The need for TLR, on the other hand, was 
higher in the DEB + BMS group compared to the DES 
group although this did not reach statistical significance 
[RR =1.57; (0.94 to 2.62); P=0.08] (Figure 4).
 MACE
Definitions of MACE had slight variations across the 
17 studies within this review. However, they were still 
interpreted under one global outcome. When compared 
to the BMS alone group, DEB + BMS had a significantly 
more favourable outcome (lower rate of MACE) [RR =0.64; 
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Records identified through 
EMBASE, MEDLINE & PubMed 
searching
(n=598) 
Records after duplicates 
removed 
(n=405)
Records screened 
(n=405)
Records excluded
(n=371)
	Observational (n=133) (case-
control, cohort, registry)
	Irrelevant (n=141)
	Review (n=56)
	Systematic review (n=2)
	Meta-analysis (n=10)
	Case Report (n=12)
	Animal model (n=9)
	Study protocol (n=2)
	Non-randomised (n=5)
	Commentary (n=1)
Records excluded
(n=17)
	Sequential-order studies (n=2)
	Study design (n=1) 
	Irrelevant (n=1)
	Study Protocol (n=1)
	Use of EPC stents (n=4)
	Follow-up studies (n=4)
	Sub-studies (n=4)
34 trials were included after 
review of title and abstract 
17 trials were included after 
review of full text
Additional records identified 
through other sources 
(n=8) 
Figure 1 Study selection process. EPC, endothelial progenitor cell-capturing stent. 
(0.46 to 0.90); P=0.010]. However, even though the rate 
of MACE was higher in the DEB + BMS group compared 
to the DES group, there was no statistically significant 
difference [RR =1.39; (0.96 to 2.01); P=0.08] (Figure 5).
MI
There was no significant differences reported between 
the DEB + BMS groups and BMS or DES groups for MI 
[RR =0.66; (0.19 to 2.29); P=0.51]; [RR =1.30; (0.60 to 2.84, 
95% CI); P=0.51] (Figure 6). 
Death
There was also no significant differences reported between 
the DEB + BMS groups and BMS or DES groups for death 
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[RR =0.20; (0.02 to 1.70); P=0.14]; [RR =1.43; (0.45 to 4.52); 
P=0.54] (Figure 7).
Stent thrombosis
Stent thrombosis out of all the outcomes had the lowest 
incident rate. No statistically significant difference 
was reported in the DEB + BMS group versus control 
[RR =1.85; (0.84 to 4.08); P=0.13]. This was also the case 
for DEB + BMS compared with BMS alone and DES alone 
[RR =4.10; (0.46 to 36.40); P=0.21]; [RR =1.64; (0.70 to 
3.83); P=0.26] (Figure 8).
Subgroup analysis
As part of the subgroup analysis, ‘DEB-only’ interventions 
were compared with DES. In terms of LLL, DEB-only had 
no statistically significant difference to DES [MD =−0.12; 
(−0.25 to 0.01); P=0.06]. This was also seen in binary 
restenosis, MACE, TLR, MI and death; binary restenosis—
[RR =1.36; (0.31 to 6.04); P=0.69], MACE—[RR =1.15; 
(0.27 to 4.98); P=0.85], TLR—[RR =1.26; (0.24 to 6.79); 
P=0.78], MI—[RR =0.65; (0.11 to 3.86); P=0.64] and 
death—[RR =0.69; (0.12 to 4.17); P=0.69].
Publication bias
Egger’s test revealed no evidence of significant publication 
bias within this meta-analysis (P>0.05). This lack of bias was 
also substantiated by the symmetrical funnel plot for our 
primary angiographic endpoint of LLL (Figure 9).
Discussion
This is the first meta-analysis to compare DEB with and 
without BMS to all three management options: POBA, BMS 
alone and DES for treatment of de novo coronary lesions. 
Of the 17 RCTs included in the study, 14 studies compared 
DEB + BMS with DES and/or BMS, two studies compared 
DEB-only to DES and one, DEB alone to POBA. 
Findings
The significant findings of this study can be summarised 
as follows: (I) DES was superior to DEB + BMS in 
angiographic (LLL) and clinical (binary restenosis) 
outcomes; (II) DEB + BMS was superior to BMS in LLL 
and clinical outcomes (MACE, TLR); and (III) DEB-
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Table 3 Risk of bias
Study
Random sequence 
generation
Allocation 
concealment
Blinding of participants 
and personnel
Blinding of outcome 
assessment 
Incomplete 
outcome data 
Selective 
reporting
Other 
bias
Chae  
et al. (17)
L 0 H L L L L
PEPCAD-
BIF (18)
L L L L L L H
BELLO 
(19,20)
L L L L L L 0
Żurakowski 
et al. (21)
0 L L L L 0 L
IN-PACT 
CORO (22)
0 0 H L L L L
Besic  
et al. (23)
0 0 L 0 L 0 0
Touchard  
et al. (24)
0 0 L 0 0 0 0
Poerner  
et al. (25)
0 0 L L H L 0
BABILON 
(26)
L 0 L L L L L
Liistro  
et al. (27)
L L H L H 0 L
Clever  
et al. (28)
0 0 L L L 0 H
Stella  
et al. (29) 
L L L L L 0 H
DEB-AMI 
(30)
L L L L H L H
Ali et al. (31) 0 0 L L L L H
PICCOLETO 
(32)
L L L L L 0 0
Herdeg  
et al. (33)
L L L L L 0 H
Hamm  
et al. (34)
0 0 L L L L H
Table highlights the various risks of biases present in the seven assessed domains. L, low risk of bias; H, high risk of bias; 0, insufficient/
unreported bias.
only approach was superior to POBA for LLL and binary 
restenosis in bifurcation lesions.
Data interpretation 
The current standard of care for PCI treatment of de novo 
coronary lesions is implantation of a second generation 
DES (35). However, there is increasing concern about the 
longer term risk of DES, such as increased bleeding risk 
with prolonged antiplatelet therapy (10,36). Additional risks 
include development of ISR and late ST which remain a 
factor of concern for DES users despite a lower incidence of 
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DEB+ BMS Control Mean difference  
Mean SD Total Mean SD Total Weight IV, Random, 95% Cl 
Mean difference 
IV, Random, 95% Cl 
0.08 0.31 25 0.47 0.61 23 4.7% -0.39 [-0.67, -0.11] 
25 23 4.7% -0.39 [-0.67, -0.11] 
0 27 0 43 27 0.6 0 55 25 48% -0 33 [-0 60, -0.06] 
0 44 0 55 50 0 52 0.66 51 51% -0 08 [-0 32, 0.16] 
0.62 0.45 54 0.95 0.77 56 5.1% -0.33 [-0.56, -0.1 OJ 
0 59 0 42 8 0 85 0.28 17 43% -0 26 [-0 58, 0.06] 
0.58 0.65 40 0.6 0.65 37 4.5% -0.02 [-0.31, 0.27] 
0.32 0.49 111 0.85 0.67 112 5.9% -0.53 [-0.68, -0.38] 
Stud:t'. or subgroue 
1.1.1 POBA 
PEPCAD-BIF (DEB+ 15.6% BMS) 2016 
Subtotal (95% Cl) 
Heterogeneity: Not applicable 
Test for overall effect: Z = 2. 76 (P = 0 006) 
1.1.2 BMS 
Clever et al 2013 
DEB-AMI 2012 
Herdeg et al. 2009 
IN-PACT CORO 2015 
Stella et al. 2012 
Touchard et al. (2015) 
Subtotal (95% Cl} 290 298 29.6% -0.27 [-0.45, -0.10] � 
Heterogeneity: Tau2 = 0.03; Chi2 = 15.32, df = 5 (P = 0.009), 12 = 67% 
Test for overall effect: Z = 3.11 (P = 0 002) 
0 37 0 59 39 0 35 0 63 36 47% 0 02 [-0 26, 0.30] 
0 25 0 48 43 0 25 0 49 43 54% 0 00 [-0 21, 0.21] 
0 05 0 37 81 0 17 0 45 82 61% -0 12 [-0 25, 0.01] 
0.3 0.46 74 0.21 0.44 72 6.0% 0.09 [-0.06, 0.24] 
0 27 0 43 27 0 28 0.4 25 52% -0 01 [-0 24, 0.22] 
0 44 0 55 50 017 035 49 56% 0 27 [O 09, 0.45] 
0.2 0.52 312 0.11 0.4 325 6.5% 0.09 [0.02, 0.16] 
0 62 0 45 54 044 058 54 55% 0.18 [-0 02, 0.38] 
1.14 59 0.34 0.7 66 4.4% 0.80 [0.49, 1.11] 
0.24 0.21 42 0.16 0.15 48 6.5% 0.08 [0.00, 0.16] 
0 58 0 65 40 0 13 0 45 40 50% 0 45 [O 21, 0.69] 
0.21 0.5 55 0.3 0.7 37 4.8% -0.09 [-0.35, 0.17] I+ 
1.1.3 DES 
Ali et al. 2011 
BABILON 2014 
BELLO (DEB+ 20.2% BMS) 2012/2015 
Chae et al. 2017 
Clever et al 2013 
DEB-AMI 2012 
Hamm et al. 2009 
Herdeg et al. 2009 
Liistro et al. 2013 
Poeme「 et al. 2014 
Stella et al 2012 
Zurakowski et al. 2015 
Subtotal (95% Cl) 876 877 65.7% 0.12 [0.03, 0.22] 
Heterogeneity: Tau2 = 0 02; Ch户= 47 80, df = 11 (P < 0.00001); 12 = 77% 
Test for overall effect: Z = 2.54 (P = 0.01) 
Total (95% Cl) 1191 1198 100.0% -0.01 [-0.12, 0.10] 
Heterogeneity: Tau2 = 0.05; Chi2 = 135.13, df = 18 (P < 0.00001), 12 = 87% 
-1 -0.5 。 0.5 
Test for overall effect: Z = 0.18 (P = 0 86) Favours [DEB + BMS] Favours [control] 
Test for subgroup differences. Ch户= 23.68, df = 2 (P < 0.00001), 12 = 91.6% 
Figure 2 Forest plot of mean differences for late lumen loss. BMS, bare-metal stents; CI, confidence interval; DEB, drug-eluting balloons; 
DES, drug-eluting stents; POBA, plain-old balloon angioplasty.
DEB+ BMS Control Risk ratio 
Events Total Events Total Weight IV, Random, 95% Cl 
2 25 9 
25 
2 9 
7 41 10 
13 50 10 
8 54 22 
2 40 5 
2 111 33 
Study_ or subgroue 
1.2.1 POBA 
PEPCAD-BIF (DEB+ 15.6% BMS) 2016 
Subtotal (95% Cl) 
Total events 
Heterogeneity: Not applicable 
Test for overall effect: Z = 2.19 (P = 0.03) 
1.2.2 BMS 
Besic et al. 2015 
DEB-AMI 2012 
Herdeg et al. 2009 
Stella et al. 2012 
Toucha「d et al. (2015) 
Subtotal (95% Cl) 296 
Total events 32 80 
Heterogeneity: Tau2 = 0.74; Chi2 = 16.85, df = 4 (P = 0.002); 12 = 76% 
Test for overall effect Z = 1 83 (P = 0.07) 
5 39 5 
7 43 
8 81 12 
9 74 2 
13 50 3 
37 312 13 
8 54 8 
15 59 3 
9 28 3 。 42 。
2 40 2 
6 55 6 
877 
1.2.3 DES 
Ali et al 2011 
BABILON 2014 
BELLO (DEB+ 20.2% BMS) 2012/2015 
Chae et al. 2017 
DEB-AMI 2012 
Hamm et al. 2009 
Herdeg et al. 2009 
Liistro et al. 2013 
PICCOLETTO (DEB + 36.0% BMS) 2010 
Poerner et al 2014 
Stella et al. 2012 
Zurakowski et al. 2015 
Subtotal (95% Cl) 
Total events 119 58 
Heterogeneity: Tau2 = 0.41; Chi2 = 23. 73, df = 1 O (P = 0.008), 12 = 58% 
Test fo「overall effect: Z = 2.40 (P = 0.02) 
23 52% 
23 5.2% 
44 6.8% 
51 72% 
56 7.2% 
37 48% 
112 5.3% 
300 31.3% 
36 60% 
43 37% 
82 6.9% 
72 5.0% 
49 59% 
325 7.5% 
54 67% 
66 5.9% 
29 5.8% 
48 
40 4.0% 
37 63% 
881 63.5% 
Total (95% Cl) 1198 1204 100.0% 
Total events 153 147 
Heterogeneity: Tau2 = 0.87; Chi2 = 66. 78, df = 16 (P < 0 00001); 12 = 76% 
Test for overall effect: Z = 0.28 (P = 0.78) 
Test for subqroup differences: Chi2 = 13.72, df = 2 (P = 0.001), 12 = 85.4% 
0.20 [0.05, 0.85] 
0.20 [0.05, 0.85] 
0.75 [0.32, 1.79] 
1.33 [0.64, 2.74] 
0.38 [0.18, 0.77] 
0.37 [0.08, 1.79] 
0.06 [0.02, 0.25] 
0.44 [0.18, 1.06] 
0.92 [0.29, 2.93] 
7 00 (0.90, 54.50] 
0.67 [0.29, 1.56] 
4.38 (0.98, 19.57] 
4 25 (1.29, 13.99] 
2.96 [1.61, 5.47] 
1.00 [0.40, 2.47] 
5.59 (1.70, 18.36] 
3.11 (0.94, 10.31] 
Not estimable 
1.00 [0.15, 6.76] 
0 67 [0.23, 1.93] 
1.89 [1.13, 3.18] 
1.08 [0.64, 1.83] 
Risk ratio 
IV, Random, 95% Cl 
I+ 
0.01 0.1 1 10 100 
Favours [DEB + BMS] Favours [control] 
Figure 3 Forest plot of risk ratios (RR) for binary restenosis. BMS, bare-metal stents; CI, confidence interval; DEB, drug-eluting balloons; 
DES, drug-eluting stents; POBA, plain-old balloon angioplasty. 
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DEB+ BMS Control Risk ratio 
Events Total Events Total Weight IV, Random, 95% Cl 
Risk ratio 
IV, Random, 95% Cl 
8 41 13 44 80% 0.66 [0.31, 1.43] 。 27 3 25 1.7% 0.13 [0.01, 2.45] 
10 50 9 51 7.7% 1.13 [0.50, 2.55] 
9 67 15 67 81% 0.60 [0.28, 1.28] 
4 20 3 10 5.3% 0.67 [0.18, 2.42] 。 40 2 37 1.6% 0.19 [0.01, 3.74] 
2 111 8 112 44% 0.25 [0.05, 1.16] 
Stud�or subgroue 
2.2.1 BMS 
Besic et al. 2015 
Cleve「 et al. 2013 
DEB-AMI 2012 
Herdeg et al. 2009 
IN-PACT CORO 2015 
Stella et al. 2012 
Touchard et al (2015) 
Subtotal (95% Cl) 356 346 36.8% 0.65 [0.44, 0.97] 令
Total events 33 53 
Heterogeneity: Tau2 = 0.00; Chi2 = 5.14, df = 6 (P = 0.53); 12 = 0% 
Test for overall effect: Z = 2.10 (P = 0.04) 
3 45 4 39 47% 0 65 [0.15, 2.73] 
8 43 2 43 4.5% 4.00 (0.90, 17.76] 
6 90 11 92 7.0% 0.56 [0.22, 1.44] 
5 90 3 90 49% 1.67 [0.41, 6.77] 。 27 4 25 1 7% 0 10 [0.01, 1.82] 
10 50 49 3.0% 9.80 [1.30, 73.69] 
28 312 13 325 8.7% 2.24 [1.18, 4.25] 
9 67 8 67 73% 1.13 [0.46, 2.74] 
15 59 3 66 5.8% 5.59 (1.70, 18.36] 
9 28 3 29 57% 3 11 (0.94, 10.31] 
51 2 48 2.4% 0.47 [0.04, 5.02] 。 40 40 1.5% 0.33 [0.01, 7.95] 
7 102 5 100 61% 1.37 [0.45, 4.18] 
2.2.2 DES 
Ali et al 2011 
BABILON 2014 
BELLO (DEB+ 20.2% BMS) 2012/2015 
Chae et al 2017 
Clever et al. 2013 
DEB-AMI 2012 
Hamm et al. 2009 
Herdeg et al. 2009 
Liistro et al. 2013 
PICCOLETTO (DEB + 36.0% BMS) 2010 
Poemer et al. 2014 
Stella et al. 2012 
Zurakowski et al. 2015 
Subtotal (95% Cl) 1004 1013 63.2% 1.57 [0.94, 2.62] 
Total events 101 60 
Heterogeneity: Tau2 = 0.38; Chi2 = 23.42, df = 12 (P = 0.02); 12 = 49% 
Test for overall effect: Z = 1.73 (P = 0.08) 
Total (95% Cl) 1360 1359 100.0% 1.08 [0.72, 1.63] 
Total events 134 113 
Heterogeneity: Tau2 = 0.40; Chi2 = 40.52, df = 19 (P = O 003); 12 = 53% 
0.005 0 1 1 10 200 Test for overall effect: Z = 0.36 (P = 0.72) Favours [DEB + BMS] Favours [control] 
Test for subqroup differences Chi2 = 7 06, df = 1 (P = 0.008), 12 = 85 8% 
Figure 4 Forest plot of risk ratios (RR) for TLR. BMS, bare-metal stents; CI, confidence interval; DEB, drug-eluting balloons; DES, drug-
eluting stents; POBA, plain-old balloon angioplasty; TLR, target lesion revascularization.
DEB+ BMS Control Risk ratio 
Events Total Events Total Weight IV, Random, 95% Cl 
Risk ratio 
IV, Random, 95% Cl 
11 41 13 44 68% 0.91 [0.46, 1.79] 。 27 4 25 1.1% 0.10 [0.01, 1.82] 
10 50 12 51 6.4% 0.85 [0.40, 1.79] 
9 67 18 67 65% 0.50 [0.24, 1.03] 
4 20 3 10 3.7% 0.67 [0.18, 2.42] 
8 40 11 37 6.1% 0.67 [0.30, 1.49] 
4 105 13 105 46% 0.31 [0.10, 0.91] 
Stud�or subgroue 
2.1.1 BMS 
Besic et al. 2015 
Cleve「et al. 2013 
DEB-AMI 2012 
Herdeg et al. 2009 
IN-PACT CORO 2015 
Stella et al. 2012 
Touchard et al (2015) 
Subtotal (95% Cl) 350 339 35.3% 0.64 [0.46, 0.90] • 
Total events 46 74 
Heterogeneity: Tau2 = 0.00; Chi2 = 5.33, df = 6 (P = 0.50); 12 = 0% 
Test for overall effect: Z = 2.59 (P = 0.010) 
6 45 6 39 48% 0 87 [0.30, 2.47] 
9 43 4 43 4.5% 2.25 [0.75, 6.75] 
13 90 23 92 7.2% 0.58 [0.31, 1.07] 
9 90 7 90 53% 1.29 [0.50, 3.30] 。 27 2 25 1 0% 0 19 [0.01, 3.69] 
10 50 2 49 3.2% 4.90 [1.13, 21.23] 
65 312 37 325 8.8% 1.83 [1.26, 2.66] 
9 67 9 67 57% 1.00 [0.42, 2.36] 
17 59 4 66 4.8% 4.75 (1.70, 13.33] 
10 28 4 29 48% 2 59 [0.92, 7.30] 
5 51 5 48 4.2% 0.94 [0.29, 3.05] 
8 40 7 40 5.4% 1.14 [0.46, 2.85] 
7 102 7 100 49% 0 98 [0.36, 2.69] 
2.1.2 DES 
Ali et al 2011 
BABILON 2014 
BELLO (DEB+ 20.2% BMS) 2012/2015 
Chae et al 2017 
Clever et al. 2013 
DEB-AMI 2012 
Hamm et al. 2009 
Herdeg et al. 2009 
Liistro et al. 2013 
PICCOLETTO (DEB + 36.0% BMS) 2010 
Poemer et al. 2014 
Stella et al. 2012 
Zurakowski et al. 2015 
Subtotal (95% Cl) 1004 1013 64.7% 1.39 [0.96, 2.01] 
Total events 168 117 
Heterogeneity: Tau2 = 0.20; Chi2 = 24.49, df = 12 (P = 0.02); 12 = 51% 
Test for overall effect: Z = 1.75 (P = 0.08) 
Total (95% Cl) 1354 1352 100.0% 1.04 [0.75, 1.42] 
Total events 214 191 
Heterogeneity: Tau2 = 0.26; Chi2 = 44.44, df = 19 (P = O 0008); 12 = 57% 
0.005 0.1 1 10 200 
Test for overall effect: Z = 0.21 (P = 0.83) Favours [DEB + BMS] Favours [control] 
Test for subqroup differences Chi2 = 9 21, df = 1 (P = 0.002), 12 = 89 1 % 
Figure 5 Forest plot of risk ratios (RR) for MACE. BMS, bare-metal stents; CI, confidence interval; DEB, drug-eluting balloons; DES, 
drug-eluting stents; MACE, major adverse cardiac events; POBA, plain-old balloon angioplasty.
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Study or subgrou 
2.3.1 BMS 
Besic et al. 2015 
Clever et al. 2013 
DEB-AMI 2012 
Herdeg et al. 2009 
IN-PACT CORO 2015 
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Figure 6 Forest plot of risk ratios (RR) for MI. BMS, bare-metal stents; CI, confidence interval; DEB, drug-eluting balloons; DES, drug-
eluting stents; MI, myocardial infarction; POBA, plain-old balloon angioplasty.
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Figure 9 Funnel plot for publication bias using the primary angiographic endpoint of late lumen loss.
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disease compared to BMS (37,38). DEB, advocated for their 
ability to reduce DAPT and promote homogeneous drug 
transfer have been proposed as an alternative to DES (39). 
However, drawbacks such as dissection and acute elastic 
recoil means that DEB treatment is often seen accompanied 
with BMS (39). 
In this analysis, it was shown that DEB + BMS were 
significantly inferior to DES in clinical and angiographic 
outcomes. Apparent lack of efficacy of DEB + BMS 
compared to DES could be explained in part by the high 
use of first-generation paclitaxel based DEB which are 
likely to be inferior to DES in terms of drug delivery. Also, 
the relatively short contact time between DEB and vessel 
wall could result in a greater ‘wash-off’ effect than with 
DES. A study investigating DEB techniques found optimal 
concentrations of paclitaxel in the vessel wall following 
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short inflation times of 30 to 45 seconds (40). The study 
which compared 1st and 2nd generation DIOR balloons in 
a porcine model also found higher tissue concentrations of 
drug and reduced arterial wall injury with 2nd generation 
DEBs (40). Coupling of 2nd generation DEBs with a shorter 
inflation time could therefore improve release kinetics and 
safety in future studies.
Different generation DES were also used. Eight trials 
used 1st generation DES, whilst five used 2nd generation 
devices. The TAXUS Liberté paclitaxel-eluting stent was 
the most common followed by the Xience V everolimus-
eluting stent. A meta-analysis which compared 1st and 
2nd generation DES found that 1st generation sirolimus-
eluting stents compared well in efficacy to 2nd generation 
everolimus/zotarolimus eluting stents in TLR, MACE and 
restenosis (41,42); whereas, 2nd generation everolimus-
based stents had better clinical outcomes (MI and ST 
rates) (41,42). Thus, it cannot be ruled out that some 
heterogeneity within results arose from a lack of uniformity 
in the DEB and DES employed. 
Implications of DEB-only approach
DEB-only intervention is currently accepted in routine 
practice for treatment of ISR, re-restenosis or for side 
branch POBA. There may also be other niche indications 
including high-risk restenotic lesions such as bifurcations, 
long lesions, diffuse disease in diabetic patients and small 
vessel disease (43). The PEPCAD-BIF trial was the first 
randomised controlled trial to explore DEB-only use in 
side branch and/or distal main branch lesions (18). The trial 
showed that for bifurcations, DEB alone had a statistically 
significant reduction in LLL and binary restenosis (18). 
Whilst not having been directly compared to DES, the 
DEB-only approach is attractive for bifurcations owing 
to preservation of vessel patency and avoidance of carina 
shift—a phenomenon largely responsible for side branch 
occlusion following DES treatment (16,18). In addition, low 
rates of restenosis and TLR seen in the PEPCAD-BIF trial 
also suggested some promise for the DEB-only treatment 
of bifurcation lesions (18). However, more randomised 
controlled trials comparing DES and DEB alone are needed 
to determine whether these theoretical benefits translate to 
better angiographic and clinical outcomes. 
Small vessel disease is another area where the DEB-
only strategy has shown potential because short drug 
transfer time and lack of foreign body implantation reduces 
higher rates of neointimal proliferation and inflammatory 
response found in smaller-calibre vessels treated with BMS 
treatment (44). This was substantiated by our findings 
which suggested that DEB alone performed comparably 
to the current mainstay of treatment, DES, for both 
clinical and angiographic outcomes. It should be noted, 
however, that our meta-analysis only presented data from 
two studies comparing DES and DEB-alone (BELLO 
and PICCOLETO) since randomised controlled trials 
concerning this topic were scarce. 
Despite these two trials portraying DEB-alone in a 
favourable light in small vessel disease, data from the 
study endpoints were rather heterogeneous. This could be 
explained by the use of IN.PACT Falcon, a 2nd generation 
DEB in the BELLO trial and DIOR I, a 1st generation DEB 
in the PICCOLETO trial. Furthermore, pre-dilatation 
rates were very low in the PICCOLETO trial compared 
with the BELLO trial (25% versus 96.8% respectively) 
(19,32). This is an important difference as pre-dilatation is a 
necessary prerequisite for optimal drug absorption through 
creation of micro-channels in the plaque and vessel wall (45). 
Importantly in this regard, studies did not also report the 
use of cutting or scoring balloon which may be important 
in improving drug access to the vessel wall. Experience has 
indicated that adequate and appropriate lesion preparation 
is essential when using DEB. It is important therefore 
that in future studies there is a standardised approach to 
lesion preparation, use of adjunctive technology such as 
cutting or scoring balloon and an adequate description of 
the methodology since it is possible that this will have an 
important effect on the efficacy of the DEB technique. 
Hence, the DEB-only approach with the right variant and 
preparation technique could show even more promise for 
small vessel lesions.
Limitations
This meta-analysis had several limitations. For example, a 
large majority of studies had a small sample size and results 
were moderately heterogeneous. However, this was likely 
the result of different generations of DEB and DES used 
as well as different study design comparators such as DES, 
POBA and BMS. For this reason, stratified and subgroup 
analyses were taken into account to further isolate sources 
of variability. Secondly, 14 trials reported clinical outcomes 
from relatively short follow-up periods (≤1 year) which may 
have failed to capture episodes of late stent thrombosis and 
thus influenced results. As already mentioned, the latest 
generations of DES and DEB were not universally studied 
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and therefore results should be interpreted with caution 
in the context of latest devices in current clinical use. 
Additionally, any future studies of DEB must be against the 
latest generation of DES so that a valid comparison can be 
made against the technology in current clinical use. Finally, 
some studies were susceptible to industry bias owing to 
author involvement in relevant device companies such as B. 
Braun, Boston Scientific Medtronic and Eurocor GmbH 
(18,21,22,28,29,31,33). Similarly, conflicts of interest may 
have arisen due to these companies funding studies which 
investigated their own products (18,21,26,28,30,31,33,34).
Conclusions
Overall, the results of this meta-analysis found that DEB 
in combination with BMS was not superior to DES in both 
clinical and angiographic outcomes for de novo coronary 
lesions. Compared to BMS alone, however, the combination 
of DEB and BMS was superior in LLL and MACE. The 
strategy of DEB alone has shown some promise. For 
example, DEB-only studies performed comparably to DES 
within the setting of small coronary vessels. In addition, the 
approach has shown early success in bifurcation lesions with 
DEB alone. These findings suggest that for major de novo 
coronary lesions, DEB + BMS should not be considered 
for treatment unless in patients who have significant 
contraindications to DES. Whilst the result from DEB-
alone may be advantageous in cases of high-risk restenotic 
lesions such as small vessel disease following successful pre-
dilatation and bifurcation lesions of certain classifications 
(Medina type 0, X, X) we conclude that DEB are still not a 
widely accepted modality of treatment.
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